Gilead Sciences

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines founded in 1987 by Michael L. Riordan.

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines that is headquartered in Foster City, California and was founded in 1987. The firm also has locations in La Vernne, California; Oceanside California; San Dimas, California; Miami, Florida; Santa Monica, California; Seattle, Washington; El Segundo, California; and Emeryville, California.

Gilead Sciences specializes in developing and commercializing biopharmaceuticals for HIV/AIDS, liver disease, hematology, oncology, inflammation, respiratory diseases, highly infectious diseases, and viral diseases. Gilead partnered with Kyverna to develop engineering T cell immunotherapies to target autoimmune diseases. The collaboration involves Kyverna’s synthetic Treg platform and synNotch, a synthetic gene expression system from the Kite unit of Gilead.

Gilead Sciences actively participates in community partnerships with COMPASS Initiative, Gilead Lift, Gilead HIV Age Positively, TRANScend, and HepConnect.

With the outbreak of COVID-19, Gilead Sciences began evaluating patients and testing remdesivir in 600 patients with moderate COVID-19 symptoms. They also began treatment of 400 patients with severe symptoms. Their results are expected in May.

Investments

Gilead Sciences has made 12 investments, 3 lead investments, and 4 exits. Notable investments made by Gilead Sciences include: Precision BioSciences, Galapagos, Phenex Pharmaceuticals, Allogene Therapeutics, National AIDS Memorial, Tmunity Therapeutics, AlloVir, Goldfinch Biopharma, Lyndra Therapeutics, and Glympse Bio. Gilead has licensed rights to filgotinib, developed by Galapagos, for rheumatoid arthritis and GLPG1690 for idiopathic pulmonary fibrosis, both in late-stage clinical studies.

Timeline

June 29, 2020
Gilead Sciences Inc announces it has set the price its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries.

Products

Product
Description
Launch date
Industry
Website
Remdesivir

An antiviral drug candidate also known as GS-5734 developed by Gilead Sciences to treat Ebola virus that shows potential to treat coronavirus 2019-nCoV.

An immunology drug developed by Galapagos and licensed to Gilead Sciences for the treatment of rheumatoid arthritis

2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

A Deo

Employee

Aaron Arvey

Employee

Aaron Banner

Employee

Abasi Ene-Obong Ph.D.

Employee

Abrar Farooqui

Employee

Aditya Jhanwar

Employee

Adrienne Eng

Employee

Adrienne Orr

Employee

Ahmed Moussa

Employee

Akshith Mithun

Employee

Alan Stowe

Employee

Alex Derchak

Employee

Alex Iserlis

Employee

Alexandria Tong

Employee

Alexej Ladonnikov

Employee

Alexis C Glasgow

Employee

Alison Dowski

Employee

Alison Lin

Employee

Alistair Barkhouse

Employee

Aliyah Sulaiman

Employee

Ambika Gopalan

Employee

Amer Raza

Employee

Amir Abbas

Employee

Amit Vora

Employee

Amrith Mylvara

Employee

Page 1 of 16
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Morrell and Reed Alexander
February 11, 2021
Business Insider
The pandemic featured a prolonged M&A drought. But these dealmakers still landed some mammoth transactions as activity roared back.
Ben Adams
February 1, 2021
FierceBiotech
Initially known as a machine learning biotech focused on cancer, Gritstone Oncology has been broadening its scope to include a very early look at treatments for COVID-19 and, now, another infectious disease.
Research and Markets
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering....
Angus Liu
December 30, 2020
FierceBiotech
By using a combination of computational screening tools, scientists at the Chinese Academy of Sciences' Shenzhen Institutes of Advanced Technology showed that Acrotech's Folotyn, a chemotherapy originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19.
Ben Adams
December 10, 2020
FierceBiotech
COVID-19 saw its infectious disease credentials reinstated this year, and, now, it's doubling down with a deal to buy out MYR.
Andrew Dunn
December 3, 2020
Business Insider
The drug companies Alexion, Blueprint Medicines, and BioMarin are top M&A targets for 2021, according to a Bloomberg Intelligence survey.
December 1, 2020
Harvard Business Review
Sponsor content from Workday.
BioSpace
November 30, 2020
BioSpace
Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease
Mark Terry
November 23, 2020
BioSpace
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here's a look.
Mark Terry
November 23, 2020
BioSpace
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here's a look.
Alex Keown
November 20, 2020
BioSpace
The World Health Organization (WHO) recommends against using Gilead Sciences' remdesivir as a treatment for COVID-19.
Michael Hiltzik
November 16, 2020
Los Angeles Times
The federal government has poured billions into COVID-19 vaccine research, but will Americans reap the profits?
Mark Terry
November 16, 2020
BioSpace
Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.
BioSpace Editorial Staff
November 10, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
Mark Terry
November 9, 2020
BioSpace
The pre-specified interim data analysis indicated the drug hit the primary objective of superiority compared to the current standard of care for women.
Mark Terry
November 5, 2020
BioSpace
It's a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
AP
August 29, 2020
@bsindia
Foster City, California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir, to be sold under the brand name Veklury
Reuters
July 10, 2020
@bsindia
Gileads remdesivir significantly improved clinical recovery and reduced the risk of death in Covid-19 patients, additional data from a late-stage study showed.
Ankur Banerjee| Reuters
July 10, 2020
@bsindia
The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials
Ben Adams
July 8, 2020
FierceBiotech
Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.